Search Form
First, enter a politician or zip code
Now, choose a category
 

Henry Waxman's Public Statements on Issue: Drugs

Office: U.S. House (CA) - District 33, Democratic
Date Title
Sept. 15, 2014 Designer Anabolic Steroid Control Act of 2014
April 29, 2014 Hearing of the Oversight and Investigations Subcommittee of the House Energy and Commerce Committee - Examining the Growing Problems of Prescription Drug and Heroin Abuse
April 8, 2014 Hearing of the Health Subcommittee of the House Energy and Commerce Committee - Examining the Implementation of the Tobacco Control Act
April 7, 2014 Hearing of the Health Subcommittee of the House Energy and Commerce Committee - Improving Predictability and Transparency in DEA and FDA Regulation
April 1, 2014 Hearing of the Health Subcommittee of the House Energy and Commerce Committee - Examining Concerns Regarding FDA's Proposed Changes to Generic Drug Labeling
Feb. 27, 2014 Hearing of the Oversight and Investigations Subcommittee of the House Energy and Commerce Committee - Counterfeit Drugs: Fighting Illegal Supply Chains
Nov. 8, 2013 Leahy Leads Coalition of Lawmakers in Welcoming the FDA's Release of Proposed Rules To Protect Consumers Using Generic Drugs
July 16, 2013 Hearing of the House Health Subcommittee of the Energy and Commerce Committee - Reforming the Drug Compounding Regulatory Framework
June 17, 2013 Rep. Waxman Statement on Supreme Court Decision on Generic Drug Competition
June 14, 2013 Hearing of the House Health Subcommittee of the Energy and Commerce Committee - Examining the Federal Government's Response to the Prescription Drug Abuse Crisis
Oct. 9, 2012 Letter to Chairman Upton, Chairman Pitts, and Chairman Stearns
March 8, 2012 Hearing of the Health Subcommittee of the House Energy and Commerce Committee - "FDA User Fees 2012: Hearing on Issues Related to Accelerated Approval, Medical Gas, Antibiotic Development and Downstream Pharmaceutical Supply Chain
March 1, 2012 Hearing of the Commerce, Manufacturing, and Trade Subcommittee of the House Energy and Commerce Committee - Prescription Drug Diversion: Combating the Scourge
Feb. 17, 2012 Letter to Margaret Hamburg, Commissioner U.S. Food and Drug Administration - Take Action on Recommendations from the FDA's General and Plastic Surgery Devices Panel
Feb. 9, 2012 Bipartisan Group of Members Introduce Legislation to Improve Access to Lower Cost Generic Drugs
Feb. 9, 2012 Hearing of the Health Subcommittee of the House Energy and Commerce Committee - "Review of the Proposed Generic Drug and Biosimilars, User Fees and Further Examination of Drug Shortages"
Feb. 9, 2012 Members Introduce Bipartisan Legislation to Improve FDA Generic Drug Approvals
Jan. 13, 2012 Rep. Waxman Statement on Generic Drug and Biosimilar User Fee Programs
Dec. 7, 2011 Synthetic Drug Control Act of 2011
Oct. 25, 2011 Letter to Chairman Upton
Oct. 13, 2011 Letter to The Honorable Patty Murray Chairwoman and The Honorable Jeb Hensarling Chairman Joint Select Committee for Deficit Reduction
Sept. 23, 2011 Hearing of the Health Subcommittee of the House Energy and Commerce Committee - "Examining the Increase in Drug Shortages"
Sept. 23, 2011 Rep. Waxman Statement on GAO Report on Drug Pricing
Sept. 9, 2011 Letter to The Honorable Jon Leibowitz Chairman Federal Trade Commission
June 16, 2011 House Democratic Leaders Introduce Legislation to Save More Than $100 Billion in Medicare Drug Costs
June 1, 2011 House Appropriations Committee Passes Bill to Weaken Critical FDA Public Health Functions
April 14, 2011 Hearing of the Commerce, Manufacturing, and Trade Subcommittee of the House Energy and Commerce Committee - "Warning: The Growing Danger of Prescription Drug Diversion"
April 13, 2011 Hearing of the Oversight and Investigations Subcommittee of the House Energy and Commerce Committee - "Import Safety: Status of FDA's Screening Efforts at the Border"
April 12, 2011 Dingell, Waxman, Pallone, & DeGette Introduce Drug Safety Enhancement Act
March 28, 2011 Letter to The Honorable Margaret Hamburg Commissioner U.S. Food and Drug Administration
March 24, 2011 Letter to Mr. Gregory J. Divis President Ther-Rx Corporation Chief Executive Officer KV Pharmaceutical Company
March 14, 2011 New GAO Report Highlights Importance of Health Care Reform Law's Medicare Drug Savings for Seniors
March 4, 2011 Letter to The Honorable Joseph R. Pitts Chairman Subcommittee on Health
Dec. 17, 2010 Dingell, Waxman, Pallone, & Stupak Introduce Drug Safety Legislation
Sept. 20, 2010 Waxman, Dingell, Pallone & Stupak Open Discussion on Potentially Historic Changes in Drug Safety Laws
July 22, 2010 Hearing of the Subcommittee on Health of the House Committee on Energy and Commerce - Pending Public Health Legislation
May 28, 2010 Tax Extenders Act of 2009
March 10, 2010 Hearing Of The Subcommittee On Health Of The House Committee On Energy And Commerce - Drug Safety: An Update From The FDA
Dec. 8, 2009 Hearing Of The Subcommittee On Health Of The House Committee On Energy And Commerce- Prescription Drug Price Inflation: Are Prices Rising Too Fast?
Nov. 3, 2009 Hearing Of The Subcommittee On Commerce, Trade And Consumer Protection Of The House Committee On Energy And Commerce- "The NFL StarCaps Case: Are Sports' Anti-Doping Programs At A Legal Crossroads?"
June 11, 2009 Hearing Of The Health Subcommittee Of The House Energy And Commerce Committee - Emerging Health Care Issues: Follow-On Biologic Drug Competition
June 10, 2009 Chairman Waxman's Statement on FTC Report on Follow-on Biologic Drug Competition
May 1, 2009 Hearing Of The Health Subcommittee Of The House Energy And Commerce Committee - The 2009 H1N1 Flu Outbreak And The United States Federal Response
March 11, 2009 Bipartisan Group of Members Introduces "Promoting Innovation and Access to Life-Saving Medicines Act"
Sept. 9, 2008 Prevent All Cigarette Trafficking Act of 2008
July 31, 2008 Senate, House Members Introduce Bill to Provide Doctors With Unbiased Information About Prescription Drugs
July 30, 2008 Animal Drug User Fee Amendments of 2008
May 1, 2008 Panel I of a Hearing of the Health Subcommittee of the House Energy and Commerce Committee - Drug Safety Provisions of the Food and Drug Administration Globalization Act Discussion Draft Legislation
April 11, 2008 Joint Statement of Chairman Waxman and Ranking Member Davis
April 2, 2008 Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008
Skip to top
Back to top